Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...

Weill Cornell Medicine researchers have discovered a way ovarian tumors cripple immune cells: by tampering with their ability ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

It sounded like science fiction to me at first sight, and I certainly didn’t fully appreciate the potential to treat and potentially cure diseases such as cancer ... for a cell therapy platform ...

“In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC).” As highlighted in the abstract of this report, approximately 20% of lung ...

In the laboratory, these T cells undergo a transformative ... the way for broader applications in cancer treatment, potentially revolutionising the landscape of immunotherapy.

When prostate cancer cells burst as a result of menadione treatment ... it’s clear that innovative approaches like this will ...